Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RYZ711
- Development stage
- Phase 2
- Lead developer
- RayzeBio
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**RYZ711** is an investigational **ACP3-targeted positron-emission tomography radiopharmaceutical** for diagnostic imaging of prostate cancer. Developed by RayzeBio following licensing of the OncoACP3 program from Philochem, RYZ711 is the diagnostic member of an ACP3-directed theranostic pair with the therapeutic candidate RYZ701. It uses a small-molecule ACP3 ligand labeled with gallium-68 to selectively visualize prostate cancer lesions by PET/CT, including tumors with low or absent prostate-specific membrane antigen expression. A Phase 1/2 multicohort imaging study is evaluating its safety, tolerability, and diagnostic performance in localized high-risk disease, biochemical recurrence, metastatic hormone-sensitive prostate cancer, and metastatic castration-resistant prostate cancer.
- Other names
- [68Ga]Ga-OncoACP3[68Ga]Ga-OncoACP3-DOTAOncoACP3OncoACP-3OncoACP 3
02
Targets
PAP (Prostatic acid phosphatase)
Beyond the preview
Go deeper on RYZ711.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RYZ711.